S&P 500   4,582.04 (+0.72%)
DOW   36,080.15 (+0.07%)
QQQ   390.13 (+1.32%)
AAPL   194.77 (+1.27%)
MSFT   369.62 (+0.22%)
META   326.72 (+2.92%)
GOOGL   136.79 (+5.21%)
AMZN   147.11 (+1.79%)
TSLA   243.12 (+1.57%)
NVDA   462.75 (+1.70%)
NIO   7.51 (-3.10%)
BABA   72.13 (+0.90%)
AMD   125.26 (+7.22%)
T   17.01 (+0.41%)
F   10.82 (+1.22%)
MU   73.64 (+0.70%)
CGC   0.71 (+1.79%)
GE   118.73 (-0.90%)
DIS   92.89 (+1.52%)
AMC   6.83 (+0.59%)
PFE   28.84 (+0.17%)
PYPL   58.50 (-1.73%)
XOM   99.23 (+0.12%)
S&P 500   4,582.04 (+0.72%)
DOW   36,080.15 (+0.07%)
QQQ   390.13 (+1.32%)
AAPL   194.77 (+1.27%)
MSFT   369.62 (+0.22%)
META   326.72 (+2.92%)
GOOGL   136.79 (+5.21%)
AMZN   147.11 (+1.79%)
TSLA   243.12 (+1.57%)
NVDA   462.75 (+1.70%)
NIO   7.51 (-3.10%)
BABA   72.13 (+0.90%)
AMD   125.26 (+7.22%)
T   17.01 (+0.41%)
F   10.82 (+1.22%)
MU   73.64 (+0.70%)
CGC   0.71 (+1.79%)
GE   118.73 (-0.90%)
DIS   92.89 (+1.52%)
AMC   6.83 (+0.59%)
PFE   28.84 (+0.17%)
PYPL   58.50 (-1.73%)
XOM   99.23 (+0.12%)
S&P 500   4,582.04 (+0.72%)
DOW   36,080.15 (+0.07%)
QQQ   390.13 (+1.32%)
AAPL   194.77 (+1.27%)
MSFT   369.62 (+0.22%)
META   326.72 (+2.92%)
GOOGL   136.79 (+5.21%)
AMZN   147.11 (+1.79%)
TSLA   243.12 (+1.57%)
NVDA   462.75 (+1.70%)
NIO   7.51 (-3.10%)
BABA   72.13 (+0.90%)
AMD   125.26 (+7.22%)
T   17.01 (+0.41%)
F   10.82 (+1.22%)
MU   73.64 (+0.70%)
CGC   0.71 (+1.79%)
GE   118.73 (-0.90%)
DIS   92.89 (+1.52%)
AMC   6.83 (+0.59%)
PFE   28.84 (+0.17%)
PYPL   58.50 (-1.73%)
XOM   99.23 (+0.12%)
S&P 500   4,582.04 (+0.72%)
DOW   36,080.15 (+0.07%)
QQQ   390.13 (+1.32%)
AAPL   194.77 (+1.27%)
MSFT   369.62 (+0.22%)
META   326.72 (+2.92%)
GOOGL   136.79 (+5.21%)
AMZN   147.11 (+1.79%)
TSLA   243.12 (+1.57%)
NVDA   462.75 (+1.70%)
NIO   7.51 (-3.10%)
BABA   72.13 (+0.90%)
AMD   125.26 (+7.22%)
T   17.01 (+0.41%)
F   10.82 (+1.22%)
MU   73.64 (+0.70%)
CGC   0.71 (+1.79%)
GE   118.73 (-0.90%)
DIS   92.89 (+1.52%)
AMC   6.83 (+0.59%)
PFE   28.84 (+0.17%)
PYPL   58.50 (-1.73%)
XOM   99.23 (+0.12%)

Syncona Share Price, News & Analysis (LON:SYNC)

GBX 124.40
-0.80 (-0.64%)
(As of 04:35 PM ET)
Compare
Today's Range
124.20
126
50-Day Range
106.20
135
52-Week Range
105
197
Volume
375,965 shs
Average Volume
608,443 shs
Market Capitalization
£832.57 million
P/E Ratio
N/A
Dividend Yield
1.61%
Price Target
GBX 230

Syncona MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.7% Upside
GBX 230 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.57mentions of Syncona in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars


SYNC stock logo

About Syncona Stock (LON:SYNC)

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

SYNC Stock Price History

SYNC Stock News Headlines

Syncona's (SYNC) "Buy" Rating Reaffirmed at Numis Securities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Freeline Therapeutics Agrees to Buyout by Syncona
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Syncona to Acquire Freeline Therapeutics
Syncona Proposes To Acquire Freeline Therapeutics
Syncona to Buy Back Up to GBP40 Mln in Shares
FTSE 250 movers: Vistry surges, Syncona sinks on write-off
Syncona downcast as eye treatment is discontinued
UPDATE 1-UK Stocks-Factors to watch on Sept 11
See More Headlines
Receive SYNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syncona and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Asset Management
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,208
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 230
High Stock Price Target
GBX 230
Low Stock Price Target
GBX 230
Potential Upside/Downside
+83.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-56,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-39,790,000.00
Cash Flow
GBX 106.60 per share
Book Value
GBX 187 per share

Miscellaneous

Free Float
N/A
Market Cap
£837.93 million
Optionable
Not Optionable
Beta
0.31
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Thomas Henderson (Age 57)
    Co-Founder & Non-Exec. Director
  • Dr. Martin Patrick Murphy Ph.D. (Age 55)
    Chief Exec. Officer
  • Mr. John McDonald (Age 58)
    Co-Founder
  • Mr. Rolf Kristian Berndtson Soderstrom ACA (Age 57)
    BA, Chief Financial Officer
  • Mr. Ben Woolven
    Bus. Strategy and Operations Partner
  • Dr. Christopher J. Hollowood Ph.D. (Age 48)
    CIO & Managing Partner of Syncona Investment Management Ltd.
  • Ms. Annabel Clark
    Head of Investor Relations and Communications
  • Mr. Andrew Cossar
    Gen. Counsel
  • Ms. Fenella Dernie
    Exec. Officer
  • Mr. Edward Eliot Hodgkin DPhil (Age 60)
    Managing Partner














SYNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Syncona stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syncona in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYNC shares.
View SYNC analyst ratings
or view top-rated stocks.

What is Syncona's stock price target for 2024?

1 analysts have issued 1-year price objectives for Syncona's shares. Their SYNC share price targets range from GBX 230 to GBX 230. On average, they expect the company's share price to reach GBX 230 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price.
View analysts price targets for SYNC
or view top-rated stocks among Wall Street analysts.

How have SYNC shares performed in 2023?

Syncona's stock was trading at GBX 181 at the beginning of the year. Since then, SYNC shares have decreased by 30.8% and is now trading at GBX 125.21.
View the best growth stocks for 2023 here
.

Is Syncona a good dividend stock?

Syncona (LON:SYNC) pays an annual dividend of GBX 2 per share and currently has a dividend yield of 1.04%.
Read our dividend analysis for SYNC.

What other stocks do shareholders of Syncona own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syncona investors own include Rexahn Pharmaceuticals (REXN), Barrick Gold (ABX), Agnico Eagle Mines (AEM), Franco-Nevada (FNV), Goldex Resources (GDX), VanEck Gold Miners ETF (GDX), Goldcorp (GG), Barrick Gold (GOLD) and Northern Dynasty Minerals (NAK).

How do I buy shares of Syncona?

Shares of SYNC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SYNC) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -